| Autor: |
Toru, Nakamura, Tsuyoshi, Hayashi, Yasutoshi, Kimura, Hiroshi, Kawakami, Kuniyuki, Takahashi, Hirotoshi, Ishiwatari, Takuma, Goto, Masayo, Motoya, Keisuke, Yamakita, Yusuke, Sakuhara, Michihiro, Ono, Eiichi, Tanaka, Makoto, Omi, Katsuhiko, Murakawa, Tomoya, Iida, Tamaki, Sakurai, Shin, Haba, Takehiro, Abiko, Yoichi M, Ito, Hiroyuki, Maguchi, Satoshi, Hirano, Akinobu, Taketomi |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Scientific reports. 12(1) |
| ISSN: |
2045-2322 |
| Popis: |
Although neoadjuvant therapy (Nac) is recommended for high-risk resectable pancreatic cancer (R-PDAC), evidence regarding specific regimes is scarce. This report aimed to investigate the efficacy of S-1 Nac for R-PDAC. In a multicenter phase II trial, we investigated the efficacy of Nac S-1 (an oral fluoropyrimidine agent containing tegafur, gimeracil, and oteracil potassium) in R-PDAC patients. The protocol involved two cycles of preoperative S-1 chemotherapy, followed by surgery, and four cycles of postoperative S-1 chemotherapy. Two-year progression-free survival (PFS) rates were the primary endpoint. Overall survival (OS) rates and median survival time (MST) were secondary endpoints. Forty-nine patients were eligible, and 31 patients underwent resection following Nac, as per protocol (31/49; 63.3%). Per-protocol analysis included data from 31 patients, yielding the 2-year PFS rate of 58.1%, and 2-, 3-, and 5-year OS rates of 96.8%, 54.8%, and 44.0%, respectively. MST was 49.2 months. Intention-to-treat analysis involved 49 patients, yielding the 2-year PFS rate of 40.8%, and the 2-, 3-, and 5-year OS rates of 87.8%, 46.9%, and 33.9%, respectively. MST was 35.5 months. S-1 single regimen might be an option for Nac in R-PDAC; however, the high drop-out rate (36.7%) was a limitation of this study. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink